GlassScriptPhysician profile
Hugh Carey
NPI 1255327276
$3,806.94
in general payments reported to CMS, 2019-2025
27 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $359 · 2021: $520 · 2022: $389 · 2023: $415 · 2024: $587 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Education: $43.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.43 |
| Education | $43.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $769.45 | 2019-2023 | Veltassa |
| Amgen INC. | $438.23 | 2019-2025 | Parsabiv, Aranesp, Tavneos |
| Astrazeneca Pharmaceuticals LP | $356.55 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $268.19 | 2020-2025 | Benlysta |
| Novo Nordisk INC | $228.69 | 2022-2025 | Ozempic, Rybelsus, Rivfloza |
| Fresenius USA Marketing, INC. | $187.80 | 2019-2024 | Velphoro |
| Akebia Therapeutics INC | $184.35 | 2019-2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $179.35 | 2023-2025 | Filspari |
| Genzyme Corporation | $126.29 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $113.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.06 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $100.06 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $94.90 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $89.92 | 2024-2025 | |
| Genentech USA, INC. | $84.57 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $77.12 | 2022-2025 | Tarpeyo |
| Xeris Pharmaceuticals, INC. | $71.30 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $69.61 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.78 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $51.23 | 2024-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $34.15 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.29 | 2021 | |
| Lilly USA, LLC | $18.09 | 2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $17.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.92 | 2019 | |
| Shire North American Group INC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.